

# FRAME

Fund for the Replacement of Animals in Medical Experiments

## ANNUAL REPORT

For the period 1 April 2001 to 31 March 2002



### Highlights of the Year

The third FRAME Annual Lecture *International Cooperation: An Essential Requirement for Replacing Animal Toxicity Tests* was given at the Royal Society of Medicine, London, on 9 October 2001, by Professor Horst Spielmann, Head of ZEBET, Berlin.

FRAME is particularly active in a number of fields, notably in the testing of endocrine disruptors and in the development of strategies for non-animal testing of existing chemical substances, prompted by recent EU legislation.

During the year, FRAME's two scientific committees have held regular meetings and have been progressing toward their objectives. The FRAME Reduction Committee has been particularly active in compiling information on strategies for improved experimental design and statistical analysis of data on animal procedures. Several training aids have been produced, and a symposium on Reduction is being organised for the autumn of 2002. The FRAME Toxicity Committee has been augmented by the formation of five working groups, all of which have started to hold meetings. Each of these groups will focus on an issue that the main committee has identified as a key area for implementing the Three Rs in toxicity testing. A workshop

is being planned for the end of 2002, to discuss the progress made by each of the groups.

FRAME staff continue to be involved in the activities of several outside bodies, including service on a number of committees (such as the US Environmental Protection

Agency's Endocrine Disruptor Methods Validation Subcommittee). A FRAME Trustee was appointed as a member of the Animal Procedures Committee. The Scientific Director continues in his role as the president of the European Society of Toxicology In Vitro.

FRAME Staff have attended several workshops and scientific meetings throughout the year, and were involved in the organisation of some of them.

Because of the general election, the All Party Parliamentary FRAME Group had to be re-registered. This was achieved despite initial problems in signing up the required number of Members. Quite a few MPs, however, felt it was essential to keep this Group alive, despite the ever-increasing number of All Party Groups in the

House. The major driving force behind this decision was the EU chemicals testing policy, and FRAME has now come up with an action plan which will be discussed at the next meeting of the Group.

### The Aims of FRAME

FRAME considers that the current scale of live animal experimentation is unacceptable and should not be allowed to continue. However, FRAME recognises that the immediate and total abolition of all animal experimentation is not possible, if vital medical research is to continue and the remaining diseases that lessen the quality of human and animal life are to be overcome, and if new consumer products, medicines, and industrial and agricultural chemicals are to be tested in order to identify potential hazards to human and animal health and to the environment.

FRAME advocates the Three Rs approach to this problem, believing that the most immediate prospects are for *reducing* the numbers of animals used through better science and better experimental design, and *refining* procedures so that the suffering of animals necessarily used is minimised, while the long-term aim of eliminating the need for live-animal experiments altogether, lies in the proper development, validation and acceptance of *replacement* alternative methods.

FRAME is a charitable trust, founded in 1969, and is controlled solely by up to six honorary trustees, who employ scientific and administrative staff to work in five main areas: namely, legislative and regulatory reform; scientific research; publications; specific campaigns; and public education.

## Personnel Changes

Dr Samantha Gray left FRAME to take up a teaching post, and Dr Caren Broadhead left FRAME to work in industry.

## FRAME Research Programme

The FRAME Research Programme will be 20 years old later in 2002 and, by way of marking this event, FRAME is producing a booklet describing the development and major achievements of its research activities.

The Research Programme is being conducted in the FRAME office, and the FRAME Alternatives Laboratory (FAL) and the Molecular Toxicology Laboratory at the University of Nottingham Medical School.

Work continues at the FAL to develop and further improve organotypic skin and eye models for the safety testing of cosmetics and toiletries. Investigations into the effects of chemicals on the differentiation of the

tracheobronchial tract are being pursued by using bronchial cells in culture. Work is also continuing on the development of screening methods for the rapid detection of chemicals that cause skin and eye irritation. The Molecular Toxicology Laboratory has embarked on a three-year project to develop a high-throughput screening system based on the use of expression of heat-shock protein genes as an early marker of toxicity.

Work in the FRAME office includes a project on the use of laboratory cats, the first phase of which has now been completed. The findings have shown a wide diversity of usage of cats in neurobiological research, involving some procedures that are likely to cause pain. The first phase of a scientific collaboration with several pharmaceutical companies to minimise the use of dogs as a second species for toxicity testing, has also been completed. FRAME continues its work on assessing the scientific use of non-human primates, and a new project has been initiated to design and develop a Web site on humane endpoints. FRAME has also been actively involved in researching several other important issues concerning animal experimentation, including the use of genetically modified animals and food toxicity testing.

## FRAME Publications

**Balls, M.** (2001). Attitudes to alternatives to animal experimentation. *ATLA* **29**, 631–632.

**Balls, M.** (2002). Replacing animal experimentation: not a question of *if*, but *when*, and *by what route*? *ATLA* **30**, 147–148.

**Bhandari, R.N.B., Riccalton, L.A., Lewis, A.L., Fry, J.R., Hammond, A.H., Tendler, S.J.B. & Shekeshoff, K.M.** (2001). Liver tissue engineering: a role for co-culture systems in modifying hepatocyte function and viability. *Tissue Engineering* **7**, 345–357.

**Bottrill, K. & Combes, R.D.** (2001). Alternatives to animal testing in microbiology and infectiology. In *Animal Testing in Infectiology. Contributions to Microbiology. Volume 9*, (ed. S.A. Weber), pp. 89–117. Basel, Switzerland: Karger.

**Bremer, S., Worth, A.P., Paparella, M., Bigot, K., Kolossov, E., Flieschmann, B.K., Hescheler, J. & Balls, M.** (2001). Establishment of an *in vitro* reporter gene assay for developmental cardiac toxicity. *Toxicology in Vitro* **15**, 215–223.

**Broadhead, C.L. & Combes, R.D.** (2001). The current status of food additives toxicity testing and the potential for application of the Three Rs. *ATLA* **29**, 471–485.

**Bull, S., Langezaal, I., Clothier, R. & Coecke, S.** (2001). A genetically engineered cell-based system for detecting metabolism-mediated toxicity. *ATLA* **29**, 703–716.

**Festing, M.F.W., Overend, P., Das, R.G., Borja, M.C. & Berdoy, M.** (2002) *Reducing the Use of Animals in Research through Better Experimental Design*, 112 pp. London, UK: Royal Society of Medicine Press Limited.

**Fry, J. & George, E.** (2001). *In vitro* toxicology in the light of new technologies. *ATLA* **29**, 745–748.

**Gray, A.C. & Clothier R.H.** (2001). The use of an *in vitro* submerged keratinocyte model to predict induction of squamous metaplasia. *Toxicology in Vitro* **15**, 427–431.

**Gray, S.** (2001). Animal tests after the genome — a reply. *The Lancet*, **357**, 1805.

**Gray, S.** (2001). More funding must go towards finding alternative non-animal methods. *BMJ* **322**, 1605.

**Hawkins, P., Morton, D.B., Cameron, D., Cuthill, I., Francis, R., Freire, R., Gosler, A., Healy, S., Hudson, A., Inglis, I., Jones, A., Kirkwood, J., Lawton, M., Monaghan, P., Sherwin, C. & Townsend, P.** (2001). Laboratory birds: refinements in husbandry and procedures. Fifth Report of the BVAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. *Laboratory Animals* **35**, Suppl 1, 1–155.

**Jenkins, E.S. & Combes, R.D.** (2002). A critique of the Animal Procedures Committee report on biotechnology. *ATLA* **30**, 131–134.

**Morton, D.B., Jennings, M., Buckwell, A., Ewbank, R., Godfrey, C., Holgate, B., Inglis, I., James, R., Page, C., Sharman, I., Verschoyle, R., Westall, L. & Wilson, A.B.** (2001). Refining procedures for the administration of substances. Fourth report of the BVAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. *Laboratory Animals* **35**, 1–41.


**Reid, L., Clothier, R.H. & Khammo, N.** (2001) Hydrogen peroxide-induced stress in human keratinocytes and its effect on bithionol toxicity. *Toxicology in Vitro* **15**, 441–445.

**Smith, D., Broadhead, C., Combes, R., Connelly, J., Descotes, G., Fosse, R., Hack, R., Jacobsen, S.D., Krauser, K., Pfister, R., Phillips, B., Rabemampianina, Y., Sanders, J., Sparrow, S., Stephan-Gueldner, M., Von Landenberg, F.** (2002). Preclinical safety evaluation using non-rodent species — an industry/welfare project to minimise dog use. *Journal of the Institute for Laboratory Animal Research*, in press.

**Todd, I., Clothier, R.G., Huggins, M.L., Patel, N., Searle, K.C., Jeyarajah, S., Pradel, L. & Lacey, K.L.** (2001). Electrical stimulation of transforming growth factor-1 secretion by human dermal fibroblasts and the U937 human monocytic cell line. *ATLA* **29**, 693–701.

## Financial Review


### Income 2001–2002



#### Total Income £623,139

- Legacies £145,588 (23.4%)
- Research £244,540 (39.2%)
- Gen. Subs. & Donations £111,460 (17.9%)
- Investments £46,993 (7.5%)
- Publications £68,750 (11.1%)
- Tech. & Prof. Services £5,808 (0.9%)

### Expenditure 2001–2002



#### Total Expenditure £730,353

- Fundraising and Publicity £49,576 (6.8%)
- Research £430,251 (58.9%)
- Establishment and Depreciation £17,697 (2.4%)
- Administration £23,325 (3.2%)
- Publications £132,949 (18.2%)
- Technical Services £76,555 (10.5%)

Total income before exceptional items was down nearly 8% in the year to 31 March 2002, compared with the previous year's level. Strict attention was paid to controlling expenses, but with research into alternatives accounting for 60% of the total expenditure, and with much of the research being carried out under medium-term contracts, it was not possible to reduce expenditure sufficiently to bring it into line with income. As a result, FRAME recorded a deficit on its ordinary activities, after the transfer of investment income generated by the endowment fund, of £107,000 for the year. In the 12 months to 31 March 2002, the combination of realised and unrealised losses on investments increased the total deficit to just less than £220,000.

Legacy income showed an improvement over the very low level of the previous year, but was still less than half the record level of the year to March 1999. In contrast, income from publications was considerably below the previous year's level, because income in that year benefited from revenue from handling the publication of the proceedings of the *3rd World Congress on Alternatives and Animal Use in the Life Sciences*: expenditure on publications was, however, well down on the previous year's level because of the absence of the costs of publishing the Congress proceedings.

Interest income fell to below the level earned in the year to the end of March 2001, because of both lower interest rates and partial erosion of FRAME's assets arising from deficits in the previous three years.

The combined effects of the losses on activities and the loss on investments meant that FRAME's balance sheet fell from £1.5 million to £1.3 million at the year's end. Of the £1.2 million total value of investments and cash in the bank and at hand at the end of the financial year, 65% was held in either banks or the Cazenove Charities Income Fund, while 35% was held in the Cazenove Charities Growth Fund or in investment trusts.

Since the year's end, three members of FRAME's staff have left, and to bring expenditure more into line with income, it is intended to replace only one of these, for the time being. Similarly, plans have been developed to bring research expenditure more into line with the corresponding income.

FRAME has sufficient liquidity to meet its current and future commitments.

The Trustees have examined the major strategic, business and operational risks that the charity faces, and confirm that systems have been established to enable regular reports to be produced, so that the necessary steps can be taken to lessen these risks.

## Donations from Trusts

FRAME gratefully acknowledges the support of the following Trusts, from which a total of £54,578 was received during the year:

The Animal Defence Trust	The Russell & Mary Foreman 1980 Charitable Trust	The Mitchell Trust
The Dorothy Askew Trust	The Ernest Ingham Charitable Trust	The Robertson Trust
Sylvia Bell Charity	The Innominate Trust	Jean Sainsbury Animal Welfare Trust
John and Susan Bowers Fund	Sir Charles Jessel Charitable Trust	Sylvanus Charitable Trust
The Briggs Animal Welfare Trust	The Karenza Foundation	Toye Charitable Trust
Basil Brown Charitable Trust	Dolly Knowles Charitable Trust	Walker 597 Trust
The Buccleuch Charitable Foundation	The Maurice Laing Foundation	Mr & Mrs O J Whitley Charitable Trust
The Richard Cadbury Charitable Trust	The Lane Charitable Trust	The Leslie Williams Trust
The Marjorie Coote Animal Charities Trust	The Miller Foundation	A B Wilson's Charitable Trust
		The D M & J Wood Deposit Trust

## Legacies Bequeathed to FRAME

Legacy Income during the year totalled £145,588. FRAME received bequests from the following supporters:

<b>Mrs Jean I N Buckley</b> of Isle of Wight	<b>Mrs Ethel J Gray</b> of Bath
<b>Miss Estelle F Burnside</b> of Exeter	<b>Miss Lilian R Martin</b> of Yelverton
<b>Miss Marjorie C E Coe</b> of London	<b>Miss Petronella F Moens</b> of Havant
<b>Mrs Annie M Collingbourne</b> of Totnes	<b>Miss Betty J Roscoe</b> of Exeter
<b>Mr Ronald W Cooke</b> of Oxford	<b>Mrs Catherine Sawyer</b> of Blackpool
<b>Mrs Ailsa M Donderis</b> of Brighton	<b>Mrs Margaret S White</b> of Whitley Bay
<b>Mrs Muriel S Fenton</b> (via Charities Aid Foundation)	<b>Miss Dorothy M Whitehead</b> of Middlewich

## FRAME Corporate Membership

### 1. Five-star Members

These are companies which donate an annual sum of £10,000 or more. Corporate benefactors may collaborate with FRAME in specific or general research projects or contribute to the general funding of FRAME.

Asda Stores Ltd  
AstraZeneca UK Ltd  
Avon Products Inc  
The Boots Company plc  
British American Tobacco  
The Gillette Company  
GlaxoSmithKline Ltd  
Lever Fabergé Ltd  
L'Oréal  
Pfizer Ltd  
Procter & Gamble Ltd  
Safeway Stores plc  
J Sainsbury plc  
Shell International Ltd  
Superdrug Stores plc  
Unilever Research

### 2. Three-star Members

These are companies which donate an annual sum of £2000–£10,000, either for a defined purpose or for general funding.

Aventis Pharma Ltd  
British Association for Chemicals Specialities  
Coty UK Ltd  
Givaudan UK  
Marks & Spencer plc  
Merck Sharp & Dohme  
Next plc  
Reckitt Benckiser plc  
SafePharm Laboratories Ltd  
Somerfield Stores Ltd  
Tesco Stores Ltd  
Waitrose Ltd

### 3. One-star Members

These are companies which donate an annual sum of £250–£2000 to the general fund. Such donations are of particular value in providing money for activities such as education and publicity, which do not involve research.

Axxis International Ltd  
S Black Ltd  
Carter-Wallace Ltd  
Colgate-Palmolive Ltd  
A & E Connock Ltd  
Covance Laboratories Ltd  
Ecover UK Ltd  
Firmenich UK Ltd  
Th Goldschmidt Ltd  
Huntingdon Life Sciences Ltd  
Inveresk Research International Ltd  
Johnson & Johnson Ltd  
Johnson Wax Ltd  
KS Biomedix Ltd  
Mercona (GB) Ltd  
Sanofi-Synthelabo Research  
Smith & Nephew Research Ltd  
Swallowfield Consumer Products Ltd  
Thor Group  
TNO BIBRA International Ltd

Russell & Burch House, 96–98 North Sherwood Street, Nottingham, NG1 4EE  
**Tel:** 0115 958 4740; **Fax:** 0115 950 3570; **e-mail:** frame@frame.org.uk; **Web site:** http://www.frame.org.uk

Registered Charity No. 259464

**Patron:** Lord Soulsby of Swaffham Prior MA DSc PhD DVSM MRCVS.

**Trustees:** Michael Balls CBE MA DPhil FIBiol, Richard Clothier BSc PhD, Michael Festing BSc DSc PhD FIBiol CStat, David Morton BVSc PhD MRCVS FIBiol, Christopher Walsh BA.